The Cancer Genome Atlas Research Network team uncovered new mutations and amplifications in their cohort of primary cervical cancers.
The firms will target 18 Latin American countries in three years, with the goal of creating a complete HPV diagnostics system for the region.
The firm is also pursuing ovarian cancer screening and head and neck cancer tests using methylation-specific PCR.
The firm's PCR-based products for HPV-associated cancers look at DNA methylation at specific genes and include several sample preparation kits.
An evaluation of more than 5,000 women attending primary cervical cancer screening showed self-collection and physician-collected samples are comparable.
The UK firm anticipates CE marking shortly and will focus on the European and Chinese markets for its multiplex PCR test for human papillomavirus genotyping.
The company's Confidence assays are designed to detect if a woman has a high-risk HPV subtype and, if so, determine her risk of developing cervical pre-cancer or cancer.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The French firm is assessing the Roche Cobas HPV test in preparation for a global Phase III clinical trial of its own therapeutic HPV vaccine.
The company and the hospital will conduct a clinical study into the detection and prevention of the disease.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.